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Abstract 
NR3C1 gene encodes the human glucocorticoid 
receptor(hGR), which is a ligand-dependent 
transcription factor and activates transcription of 
glucocorticoid-responsive genes through binding 
directly to glucocorticoid response elements(GREs) 
in their promoter region, or modulating 
transcriptional activity of other transcription factors 
through protein-protein interactions. hGR is 
implicated in a broad spectrum of biochemical 
physiologic functions, which are essential for life, 
and has also a key role in the maintenance of basal 
and stress-related homeostasis. Almost 20% of the 
genes expressed in human leukocytes are regulated 
positively or negatively by the hGR. Approximately 
every cellular, molecular and other physiologic 
network in the human body are influenced by this 
receptor and more specifically growth, reproduction, 
intermediary metabolism, immune and 
inflammatory reactions, as well as central nervous 
system and cardiovascular functions and 
lymphoproliferative disorders, cellular proliferation 
and differentiation in target tissues and normal renal 
tubular function and thus water and electrolyte 
homeostasis are only some of the examples where 
hGR is implicated(Nicolaides, Galata, Kino, 
Chrousos, and Charmandari, 2010). 
Identity 
Other names: GCCR, GCR, GR, GRL 
HGNC (Hugo): NR3C1 
Location: 5q31.3 
Figure 1. Human hGR/NR3C1 gene 5' Flanking Region 
NR3C1 (nuclear receptor subfamily 3, group C, member 
1/glucocorticoid receptor) 
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Fig. 2A. Genomic structure of the human glucocorticoid receptor (hGR/NR3C1) gene. It is composed of 9 exons. Alternative 




The human NR3C1 gene spans a length of 157,582 
bases. The NR3C1 structural gene is composed of 
nine exons and is located in chromosome 5 
(5q31.3)(Hollenberg et al., 1985)(Figure 2A). 
Transcription 
The NR3C1 gene expresses mainly two mRNAs 
through alternative use of exons 9alpha and 9beta, 
producing two highly homologous receptor 
isoforms, termed alpha and beta(N. Z. Lu and 
Cidlowski, 2005). They are identical through amino 
acid 727, with hGRalpha having an additional 50 
amino acids and hGRbeta having an extra no 
homologous 15 amino acids (Fig. 2A). Their 
molecular weights of hGR9alpha and hGR9beta are 
97 and 94 kDa, respectively. Except these products, 
the NR3C1 gene expresses GR? (gamma), which has 
one amino acid insertion due to splicing variation at 
exon 3-4 boundary,(Meijsing et al., 2009) and GR-P 
isoform, which has only 676 amino acids and is 
encoded by an mRNA expressed from exons 1-7, but 
lacking exons 8 and 9 and unknown biologic 
significance(Hagendorf et al., 2005). The human GR 
gene has eleven different promoters with their 
alternative first exons (1A1, 1A2, 1A3, 1B, 1C, 1D, 
1E, 1F, 1H, 1I and 1J) (Figure 1). Therefore, the 
human GR gene can produce eleven different 
transcripts alternating the different promoters that 
encode the same GR proteins having a common exon 
2, which contains the translating ATG codon. 1A1, 
1A2, 1A3 and 1I are located in the distal promoter 
region spanning ~32,000-36,000 bps upstream of the 
translation initiation site, while 1B, 1C, 1D, 1E, 1F, 
1H and 1J position in the proximal promoter region 
located upstream up to ~5,000 bps. Alternate use of 
these promoters, differentiate the levels of GR 
protein isoforms in various tissues(Presul, Schmidt, 
Kofler, and Helmberg, 2007). Different splicing and 
translational GR isoforms originating from alternate 
promoters constitute up to 256 different 
combinations of homo- and hetero-dimers with 
different expression levels and transcriptional 
activities.  
This marked diversity in the transcription/translation 
of the GR gene allows cells/tissues to accommodate 
appropriately to the circulating concentrations of 
glucocorticoids depending on their needs(Chrousos 
and Kino, 2005a) and is responsible for the highly 
stochastic nature of the glucocorticoid-signaling 
pathway (Chrousos and Kino, 2005b). 
Pseudogene 
The NR3C1 gene has a pseudogene (NC3C1P1) in 
chromosome 16q (provided by RefSep 2012) 
Protein 
Description 
The human NR3C1 protein sequence 
(NP_000167.1)consists of 777 amino acids and has 
a MW of 85659 Da. Without the presence of the 
ligand, hGRalpha takes part in a heteromultimeric 
cytoplasmic complex with chaperone Heat Shock 
Proteins (HSP)90,70,50 immunophilins and other 
proteins.  
NR3C1 (nuclear receptor subfamily 3, group C, member 
1/glucocorticoid receptor) 
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Fig 2B. Functional domains of the NR3C1/hGRalpha. AF, activation function; DBD, DNA-binding domain; HSPs, heat shock 
proteins; LBD, ligand-binding domains; NLS, nuclear localization signal. 
 
As soon as it binds to the ligand, dissociates from the 
previous complex and FK506-binding 
immunophilin heat shock protein 56 takes its place, 
thereby connecting to dynein and mediating the 
transportation to the nucleus, where it dissociates 
(Czar, Lyons, Welsh, Renoir, and Pratt, 1995). When 
it reaches the nucleus, the receptor binds as a 
homodimer to various Glucocorticoid Response 
Elements(GREs) sequences in the promoter region 
of many genes, and as a heterodimer with NR3C2 or 
the retinoid X receptor, thus regulating their 
expression either positively or negatively depending 
on GRE sequence and promoter context. The ligand-
activated hGRalpha modulates gene expression 
without binding to GREs, by interracting also with 
other transcription factors, such as activator protein-
1(AP-1), nuclear factor-kB (NF-kB), p53 and signal 
transducers and activators of transcription (STATs). 
For the transcription when hGRalpha uses its 
transcriptional activation domains, AF-1 and AF-2, 
as surfaces to interact with specific nuclear receptor 
coactivators and chromatin-remodeling complexes, 
then these coactivators form a bridge between DNA-
bound hGRalpha and the transcription initiation 
complex, conveying the transmission of the 
glucocorticoid signal to the RNA polymerase II and 
its ancillary components leading to initiation and 
promotion of the transcription. As a member of the 
nuclear receptor superfamily, hGR has 3 major 
domains: the N-terminal domain (NTD), middle 
DNA-binding domain (DBD) and the C-terminal 
ligand-binding domain (LBD) as illustrated in (Fig. 
2B). Using the typical nomenclature for NR 
subdomains, hGR consists of the amino-terminal 
A/B region (corresponding to NTD), C (DBD), D 
(hinge region) and E (LBD) regions, without having 
the F region. The N-terminal domain (NTD) consist 
of transactivation domain, termed activation 
function (AF)-1, located between amino acids 77 and 
262, activated when is ligand-independent. It has an 
important role in the interaction of the receptor with 
molecules necessary for stimulation of transcription, 
such as coactivators, chromatin modulators and 
basal transcription factors. The DNA-binding 
domain (DBD) consists of amino acids 420-480, 
contains two zinc finger motifs through which binds 
to specific DNA sequences, such as the 
glucocorticoid response elements (GREs) in the 
promoter region(s) of specific genes. The DBD also 
contains sequences important for receptor 
dimerization and nuclear translocation. The hinge 
region gives flexibility connecting DBD with LBD 
by conferring structural flexibility in the receptor 
dimers, allowing single receptor dimmer to interact 
with multiple GREs and different sequences. The 
ligand-binding domain (LBD) consist of amino acids 
481-777, binds ligand glucocorticoid with its ligand-
binding pocket and contains a second transactivation 
domain, the ligand-depended AF-2 which plays an 
important role in the glucocorticoid-induced 
stimulation of hGR transcriptional activity, by 
interacting with coactivators containing LxxLL 
motifs. LBD takes part in the complex formation 
with heat shock proteins, in the process of nuclear 
translocation and receptor dimerization (Nicolaides, 
et al., 2010). 
Expression 
Ubiquitous. Almost all human tissues and cells are 
expressing the hGRalpha. The GR expression has 
been reported in the Bone Marrow, Monocytes, 
Dendritic Cells, NK Cells, T Cells (CD4+), T Cells 
(CD8+), B Lymphoblasts, B Cells, Lymph Node, 
Spleen, Thymus, Retina, Heart, Cardiac Myocytes, 
NR3C1 (nuclear receptor subfamily 3, group C, member 
1/glucocorticoid receptor) 
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Atrioventricular Node, Smooth Muscle, Skeletal 
Muscle, Appendix, Pancreatic Islet, Small Intestine, 
Colon, Adipocyte, Kidney, Liver, Lung, Trachea, 
Bronchial Epithelium, Tongue, Thyroid, Salivary 
Gland, Adrenal Gland, Breast, Skin, Ovary, Uterus 
Corpus, Uterin Cervix, Placenta, Fetal Brain, Liver, 
Lung and thyroid, Tonsil, Prefrontal Cortex, 
Cingulate Cortex, Parietal Lobe, Temporal Lobe, 
Occipital Lobe, Ciliary Ganglion, Globus Pallidus, 
Olfactory Bulb, Thalamus, Hypothalamus, 
Subthalamic Nucleus, Caudate Nucleus, Amygdala, 
Pons, Medulla Oblongata, SupCervical Ganglion, 
Dorsal Root Ganglion, Trigeminal Ganglion, Spinal 
Cord, Pineal (Day)and Pineal (Night), Pituitary, 
Prostate, Testis Germ, Testis Intersitial, Testis 
Leydig cells. 
Localisation 
In the absence of ligand, hGRalpha resides mostly in 
the cell cytoplasm, but upon ligand-induced 
activation, the receptor dissociates from the 
multiprotein complex and translocate into the 
nucleus. After binding to specific DNA responsive 
elements remains within the nucleus for a 
considerable length of time and is then exported to 
the cytoplasm. It is also present in the Mitochondrion 
and Plasma membrane. The isoform Beta is mainly 
expressed in the nucleus. 
Function 
hGR has a dual mode of transcriptional activity: 
acting either as a glucocorticoid-dependent 
transcription factor, binding mainly to 
glucocorticoid response elements (GRE) or 
functioning as a modulator of other transcription 
factors through protein-protein interaction. Post-
translational modifications (PTMs), such as 
phosphorylation, acetylation, ubiqutilation and 
nitrosylation, play also an important role in the 
regulation of GR activity, affecting the receptor 
stability, subcellular localization, and also 
interaction between GR and other proteins, 
influencing finally the transcriptional activity. 
Recent studies have demonstrated that the circadian 
rhythm transcription factors CLOCK and BMAL1 
repress GR-induced transcriptional activity by 
acetylating several lysine residues (Kino and 
Chrousos, 2011). 
Homology 
Is a member of the nuclear hormone receptor family, 
NR3 subfamily. 
Mutations 
Mutations or polymorphisms in the hGR gene impair 
one or more of the molecular mechanisms of 
hGRalpha action and as a final consequence alter the 
tissue sensitivity to glucocorticoids. Reduced 
affinity of the mutant receptors for the ligand, altered 
subcellular localization, delayed nuclear 
translocation after binding to the ligand, reduced 
ability to bind with GREs and decreased 
transcriptional activity, altering the exertion of a 
dominant negative effect upon the wild-type 
receptor, reduced interaction with other coactivators 
and reduced motility within the nucleus are some of 
the mechanisms of mutant hGR (Charmandari, 
Chrousos, and Kino, 2009). Although, most 
mutations of the NR3C1 gene exert generalized 
glucocorticoid resistance there is one mutation 
reported to date in the hGRalpha NTD region that 
replaces aspartic acid at amino acid 401 by histidine 
(D401H) facilitating the mediated gene expression 
(Charmandari et al., 2008). Interindividual variations 
in tissue sensitivity to glucocorticoids have been 
described within the normal population and are 
mainly attributed to polymorphisms in the hGR 
gene. A heterozygous polymorphism replacing 
aspartic acid to serine at amino acid 363 mildly 
increases transcriptional activity, and arginine to 
lysine replacement at amino acid 23 is associated 
with relative glucocorticoid resistance. A single 
nucleotide polymorphism that replaces A with G at 
the nucleotide 3669 (A3669G) located in the 3' end 
of exon 9beta increases the stability of GRbeta 
mRNA, leading to greater inhibition of GRalpha-
induced transcriptional activity and thus 
glucocorticoid resistance (Syed et al., 2006). 
It is worth mentioning also the fact that there is a 
plethora of laboratory generated mutated GR 
proteins, which provides an interesting tool for 
exploring hGR structure-function relationships. 
(Beck, De Bosscher, and Haegeman, 2011) 
Implicated in 
Normal physiology and homeostasis 
The stochastic nature of glucocorticoid signaling 
pathways(Chrousos and Kino, 2005b), and the 
variable effect that hGR gene 
mutations/polymorphisms exert on glucocorticoid 
signal transduction, suggest that alterations in hGR 
action affect many critical biological processes 
including the behavioural and physiologic responses 
to stress, the immune and inflammatory reaction, the 
process of sleep, growth and reproduction. It is an 
extremely important component of many cellular 
and molecular signaling pathways in maintaining 
homeostasis and preserving normal physiology 
(Charmandari and Kino, 2010) 
Primary MyeloFibrosis(PMF) 
The frequency of A3669G single nucleotide 
polymorphism (SNP) of human glucocorticoid 
receptor is increased in patients with polycythemia 
vera compared to normal population.  
NR3C1 (nuclear receptor subfamily 3, group C, member 
1/glucocorticoid receptor) 
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Table 1: Reported mutations in the hGR/NR3C1 gene causing either generalized glucocorticoid resistance or increased 
sensitivity. 
 
This variant allele at the homozygous state (G/G) is 
considered also a susceptibility allele to PMF. 
Especially, in cooperation with other mutated genes 
such as JAK2V617F, the glucocorticoid receptor 
A3669G SNP contributes to the phenotype of excess 
myeloproliferation, and determination of Blast 
Transformation (Poletto et al., 2012). 
Acute Lymphoblastic Leukemia (ALL) 
Glucocorticoids (GC) are pivotal in the treatment of 
acute lymphoblastic leukemia (ALL) and other 
lymphoid malignancies, since they induce apoptosis 
in lymphoblasts. Although research studies 
delineated the transcriptional response to GCs in two 
ALL cell lines (precursor B-ALL and T-childhood 
ALL), forming mainly the basis for the molecular 
understanding of their antileukemic (and perhaps 
other) effects; questions on their induction of 
apoptosis and cell cycle arrest in leukemic cell lines 
studied still exists. Although a wide range of 
possible interacting genes were analysed (c-myc and 
Cyclin D3, BMF, MCL1, Bcl-XL, PMAIP1/Noxa, 
ZBTB16, SLA, PFKFB2, TNFAIP8, 
GPR65/TDAG8,DDIT4/Dig2, MAP2K3, MYC, 
mir17~92, TXNIP) indications were that they had 
only moderate influence if any, on GC-induced 
apoptosis in the experimental systems mentioned 
with the only exception of members of the BCL2 
gene family. Could it be a single critical gene 
downstream responsible for the GR apoptosis 
induction or rather a GC-regulated network of genes; 
this is still under investigation (Rainer et al., 2012). 
However, GC-resistance is major therapeutic 
problem without yet a clear molecular mechanism. 
In two key models of acute lymphoblastic leukemia 
the GCs resistance was associated with mutations at 
the level of the glucocorticoid receptor (some of 
which were newly identified; previously not 
associated with GC resistance, such as: A484D, 
P515H, L756N, Y663H, L680P, and R714W0 
(Schmidt et al., 2006). The survival probabilities in 
children with ALL were associated with 
homozygocity of G allele of the NR3C1 BcII 
polymorphism, presenting a worse progression and 
prognosis of the disease (Fleury et al., 2004), and 
also three other NR3C1 SNPs polymorphism; 
?627A/G, intron2 +646)C/T and 9bT/C were 
associated with dismal childhood cALL outcome 
with reduced event-free and overall survival (Labuda 
et al., 2010) 
Multiple Myeloma 
Downregulation of GR mRNA in a glucocorticoid 
resistant Multiple Myeloma cell line is in partly 
explained by the transcriptional block at intron B of 
NR3C1 (Sanchez-Vega and Gandhi, 2009). Novel 
Glucocorticoid-based therapy based on combination 
of selective glucocorticoid receptor (GR) activators 
(SEGRA) and proteasome inhibitors are effective in 
the treatment of Multiple Myeoloma, circumventing 
the undesired effects of chronic use of 
glucocorticosteroids. The novel non-steroidal GR 
modulator Compound A (CpdA) retains 
glucocorticoid-like anti-inflammatory and anti-
NR3C1 (nuclear receptor subfamily 3, group C, member 
1/glucocorticoid receptor) 
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cancer activity and has fewer side effects compared 
to glucocorticoids. (Sommer and Ray, 2008) CpdA 
strongly inhibits growth and viability of multiple 
myeloma cells in GR-dependent manner. There is 
evidence for an important GR-dependent 
cooperation between CpdA and proteasome-
inhibitor Bortezomib in eliminating survival of 
multiple myeloma cells (Lesovaya et al., 2013). 
Osteosarcoma (OS) 
Osteoblasts are highly sensitive to glucocorticoids, 
which reduce their proliferation and show apoptosis 
upon glucocorticoid treatment. In contrast to normal 
osteoblasts, OS cells express 11beta-hydroxysteroid 
dehydrogenase type 2 (11beta-HSD2), which 
converts cortisol (active) to cortisone (inactive), and 
thus, expression of 11beta-HSD2 renders OS cells 
resistant to glucocorticoids and subsequent 
apoptosis. High 11beta-HSD2 expression is 
correlated with a poor response to GCs treatment in 
Osteosarcoma (Patel et al., 2012). 
Prostate Cancer 
Glucocorticoids are used in clinical practise for 
patients with hormone-refractory prostate cancer. 
They inhibit tumour angiogenesis and subsequent 
tumour growth, possibly by down-regulating 
vascular endothelial growth factor (VEGF) and 
interleukin-8 and additionally supressing tumour-
associated lymphangiogenesis by down-regulating 
VEGF-C through glucocorticoid receptor (Yano et 
al., 2006). 
Ectopic ACTH-producing tumours 
Non-pituitary (ectopic) ACTH secretion generally is 
not responding to exogenous glucocorticoid 
administration. DMS-79 small-cell lung carcinoma 
cells derived from these ectopic ACTH-producing 
tumours express an abnormal GR mRNA which 
encodes a protein lacking the steroids-binding 
domain leading to misfunctional characteristics of 
this ligand-activated transcription factor. The 
abnormal transcripts in these cells arrived from 
normal GR genes by aberrant splicing of intron G 
(between exons 7 and 8). Although GR signalling 
defects seem likely to cause glucocorticoid 
resistance of non-pituitary tumours, the suppression 
at high doses of exogenous glucocorticoids as is 
appeared particularly in bronchial carcinoids 
implicates other potential mechanisms are also 
possible(Parks, Turney, Detera-Wadleigh, and 
Kovacs, 1998). 
Non-Small Cell Lung Cancer (NSCLC) and Small 
Cell Lung Cancer (SCLC). High levels of hGR in 
patients with advanced NSCLC are associated with 
better outcome (Y. S. Lu et al., 2006). GR expression 
causes activation of the apoptotic pathway as 
evidenced by marked induction of caspase-3 
activity. On the other hand methylation  
analysis revealed that there was significantly 
increased DNA methylation in the 1C promoter of 
the NR3C1, which was negatively correlated with 
GR protein expression in tested human SCLC cells 
(Kay et al., 2011). 
Pituitary Adenoma and 
Adrenocortical tumours 
The expression of the GR is an essential element of 
the negative closed feedback loop formed by 
corticotropin-releasing hormone, 
adrenocorticotropic hormone, and cortisol in the 
context of the hypothalamic-pituitary-adrenal (HPA) 
axis. The variability in expression and function of 
the GR in pituitary and adrenocortical cells is 
responsible for the considerable differences in 
function of this loop. Some of the variation can be 
ascribed to functional GR polymorphism, which 
may also predispose to adrenocortical tumour 
formation (Majnik et al., 2006). This variability may 
explain why it is so difficult to interpret (or 
reproduce) results regarding the analysis of 
diagnostic testing of the HPA axis in patients with 
pituitary adenomas (Cushing disease) or 
adrenocortical tumours (Cushing syndrome). 
(Briassoulis, Damjanovic, Xekouki, Lefebvre, and 
Stratakis, 2011) 
Astrocytoma 
Glial tumour cells are sensitive to glucocorticoids 
(GC), which cross the blood-brain barrier and are 
used for certain glial tumours treatment. Although 
low-grade malignant human astrocytoma cells did 
not present a significant hGRalpha expression they 
did endogenously express the Cortisol Binding 
Globulin (CBG). Upon GCs treatment CBG is 
immediately released (possibly in a nongenomic 
way) suggesting the apoptosis of certain glial 
tumours is partly associated with this phenomenon 
of CBG-release and not through hGR (Pusch, 
Wegmann, Caldwell, and Jirikowski, 2009) 
Sarkoma Kaposi (KS) 
Human Immunodeficiency Virus/Acquired 
Immunodeficiency Syndrome (HIV/AIDS)-KS cells 
expressed unusually high levels of glucocorticoid 
receptor protein and at the same time were 
significantly stimulated by glucocorticoids 
(Enwonwu, 1996). The increased expression of 
functional GRs was associated with four cytokines, 
namely interleukin-1beta, interleukin-6, tumour 
necrosis factor-alpha, and oncostatin M, all of which 
are known autocrine growth factors for AIDS-KS 
cells. The high levels of GR expression in these cells 
and the up-regulation of GRs by KS-growth-
promoting factors are associated with the enhanced 
and sustained sensitivity to the actions of 
glucocorticoids (Guo et al., 1996). 
NR3C1 (nuclear receptor subfamily 3, group C, member 
1/glucocorticoid receptor) 
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Cancers of the Digestive System 
GR is strongly expressed in oesophageal squamous 
epithelia, pancreatic islet cells and hepatocytes, but 
generally it has a weak or negative expression in 
non-squamous epithelia (gastric and colorectal 
adenocarcinomas). Chemotherapy resistance in 
tumours originating from the above mentioned 
tumour-cells induced by the use of Dexamethasone 
(DEX) is suggesting that GR expression may be 
biologically important in some GR-expressing 
carcinomas (Lien et al., 2008). In Gastric 
Carcinoma, NR3C1 methylation was a useful marker 
for identifying distinct type-subsets of these 
carcinomas (Kang et al., 2008). Analysis of tissues 
sections in well differentiated pancreatic 
adenocarcinomas revealed a strong positivity 
(mainly cytoplasmic) for Glucocorticoid receptor, 
but interestingly the liver metastasis of these 
tumours was completely negative(Bekasi and 
Zalatnai, 2009). 
Colorectal cancer 
A significant difference in mRNA expression 
(reduced) of hGRalpha, 11beta-HSD-
1(overexpressed) and other glucocorticoid 
metabolism-related genes was observed in colorectal 
adenocarcinomas which were associated with the 
downregulation of E-cadherin mRNA, a critical 
required step in the progress of tumor invasiveness, 
connecting these genes to carcinogenesis and 
progression of colorectal cancer(Storkson et al., 
2012). Cancer-specific hypermethylation of the 
NR3C1 gene was identified in colorectal tumors 
(Lind et al., 2006) and  FK506-binding proteins 
(FKBPS) suppressed the proliferation of colorectal 
adenocarcinoma possibly due to the suppression of 
function of the glucocorticoid receptor (Mukaide et 
al., 2008). 
Cervical Cancer 
GR expression is observed in cervical low and high-
grade intraepithelial neoplasia and in invasive 
cervical squamous cell carcinoma. Since 
glucocorticoids act also as cofactor with human 
papillomaviruses in the etiology of cervical cancer, 
and inhibit chemotherapy or radiation-induced 
apoptosis, the persistence of GR in cervix cancer 
cells questions the combined use of 
glucocorticosteroids with antineoplastic drugs or 
other agents in clinical practise settings for women 
presenting with cervix cancer. (Buxant, Bucella, 
Anaf, Simon, and Noel, 2009) 
Breast cancer 
Glucocorticoid receptor (GR) is playing an 
important role in mammary gland development and 
differentiation, and has been implicated in breast 
tumourigenesis without actually knowing the exact 
biochemical pathways or consequence of this unique 
expression of GR in terms of progression of Breast 
Cancer. It is strongly expressed in metaplastic 
carcinomas and malignant phyllodes tumour but 
there is lack of important GR expression in great 
majority of non-metaplastic carcinomas (Lien et al., 
2006). Glucocorticoid Receptor and Nuclear Factor 
Nf?BETA signaling pathways appears to be an 
important phenomenon in the initiation, progression 
and recurrence of inflammatory Breast Cancer (BC), 
wherein NFkB and glucocorticoid receptor (GR) are 
critical transcription factors in regulating 
inflammation. NFkB is generally pro-inflammatory, 
while GR is anti-inflammatory. It is the crosstalk 
between these two transcription factors that exert a 
crucial function in determining the survival or 
apoptosis of BC cells. However, the use of 
Glucocorticosteroids (GCs) and their biological 
effects through GR unexpectedly promote cancer 
cell survival and induce chemo-resistance in BC 
(Ling and Kumar, 2012). Curcumin which exerts a 
wide spectrum of anti-inflammatory, anti-oxidant 
and anti-cancer activities is under investigation as 
chemopreventive and chemotherapeutic agent which 
main action is through GR and NFkB modificatory 
expressions (Sinha, Biswas, Sung, Aggarwal, and 
Bishayee, 2012). 
Coronary Artery Disease 
Development of Epicardial Adipose Tissue is not 
augmented by glucocorticoids, as does the 
Subcutaneous Adipose Tissue. The decreased total 
GR mRNA expression and reduced associated 
transcripts in promoter B and C into this specific 
tissue; suggest a protective role for Coronary 
physiology (Silaghi, Silaghi, Scridon, Pais, and 
Achard, 2012) 
Bronchial asthma 
The N363S single nucleotide polymorphisms 
(SNPs) of the hGR/NR3C1 gene are supposed to 
play an important role in the development of 
bronchial asthma and in the alteration of sensitivity 
to Glucocorticosteroids in severe bronchial asthma 
(Panek et al., 2012). At the cellular level the 
impairment of GR-Ser211 phosphorylation in 
Airway Smooth Muscle cells by proasthmatic 
cytokines drastically reduced their responsiveness to 
glucocorticoids (Bouazza et al., 2012) and the use of 
glucocorticoid Dexamethasone repressed the 
production of mucin glycoproteins in lung epithelial 
cancer cells. This repression is induced by lower 
expression of mucin genes, which is mediated by the 
glucocorticoid receptor (GR) and two glucocorticoid 
response elements (GREs) in the mucin gene 
promoter region (Chen et al., 2012). 
Adult Onset Chronic Diseases 
Extreme maternal psychosocial stressors and early 
life experiences in utero and in newborns modify 
locus-specific epigenetic marks in the newborn 
NR3C1 (nuclear receptor subfamily 3, group C, member 
1/glucocorticoid receptor) 
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correlating these events with the newborn 
methylation in the promoter of the glucocorticoid 
receptor NR3C1.  
Increased methylation impairs plasticity in 
subsequent NR3C1 gene expression and accordingly 
the range of future stress adaptation responses, 
resulting possibly in increased risk for adult-onset 
diseases (Mulligan, D'Errico, Stees, and Hughes, 
2012). 
Rheumatic Diseases 
The specific actions of the hGR appear to play an 
important role in the regulation of the immune 
system and consequently play a specific role in 
diseases such as Rheumatoid arthritis, Systemic 
Lupus erythematosus, and ankylosing spondylitis. It 
is the splicing isoform GRbeta which is highly 
expressed in these patients that exert a negative 
effect on GRalpha and leads to resistance to 
glucocorticoids. Proinflammatory cytokines and the 
presence of a single nucleotide polymorphism in the 
3' untranslated region of the hGRbeta mRNA 
(rs6198G allele) are responsible for the increased 
presence of the splicing variant GRbeta (Kino, 
Charmandari, and Chrousos, 2011). 
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